Tumor-associated antigens on U87 glioblastoma cells

Tumor-associated antigens (TAAs) on U87 glioblastoma cells refer to a collection of proteins and molecules expressed by the U87-MG cell line, a standard model for human glioblastoma research. These antigens include several high-profile therapeutic targets such as the epidermal growth factor receptor (EGFR), interleukin-13 receptor alpha-2 (IL-13Rα2), HER2 (ERBB2), and survivin (BIRC5), which are involved in critical oncogenic processes like signal transduction, cell proliferation, and evasion of apoptosis [1, 3]. In research and clinical development, these antigens are targeted using various modalities, including monoclonal antibodies, CAR-T cells, and vaccines, to selectively eliminate malignant cells [2, 10]. However, the term is considered incorrect as a single target because it encompasses a heterogeneous group of molecules rather than a specific protein entity. Therapeutic strategies focusing on these antigens must contend with challenges such as the blood-brain barrier, intratumoral heterogeneity, and the risk of antigen escape, where the tumor evolves to lose the target antigen under selective pressure [2, 6]. The U87-MG cell line is one of the most frequently studied glioblastoma models, although its genetic profile may differ from primary patient tumors, particularly regarding the expression of the EGFRvIII mutation [4, 8]. Despite these limitations, the TAAs identified on U87 cells serve as a foundational platform for testing novel immunotherapies and understanding the mechanisms of glioma progression [1, 9].

Other names

U87-MG associated antigensU87 surface antigensGlioblastoma-associated antigens (U87)U87-derived tumor antigensU87-TAAs

Targeting of specific surface proteins to inhibit oncogenic signaling pathways, induce antibody-dependent cellular cytotoxicity (ADCC), or facilitate T-cell mediated destruction of glioblastoma cells.